HUP0200244A2 - Use of sex hormones for producing nasal pharmaceutical compositions useful in the treatment of undesirable uterine bleeding - Google Patents

Use of sex hormones for producing nasal pharmaceutical compositions useful in the treatment of undesirable uterine bleeding

Info

Publication number
HUP0200244A2
HUP0200244A2 HU0200244A HUP0200244A HUP0200244A2 HU P0200244 A2 HUP0200244 A2 HU P0200244A2 HU 0200244 A HU0200244 A HU 0200244A HU P0200244 A HUP0200244 A HU P0200244A HU P0200244 A2 HUP0200244 A2 HU P0200244A2
Authority
HU
Hungary
Prior art keywords
treatment
pharmaceutical compositions
compositions useful
uterine bleeding
sex hormones
Prior art date
Application number
HU0200244A
Other languages
Hungarian (hu)
Inventor
Yannis Tsouderos
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of HUP0200244A2 publication Critical patent/HUP0200244A2/en
Publication of HUP0200244A3 publication Critical patent/HUP0200244A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0200244A 1999-03-31 2000-03-30 Use of sex hormones for producing nasal pharmaceutical compositions useful in the treatment of undesirable uterine bleeding HUP0200244A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9904022A FR2791572A1 (en) 1999-03-31 1999-03-31 Treating undesirable uterine bleeding, e.g. as side-effect of hormone therapy, by intranasal administration of estradiol

Publications (2)

Publication Number Publication Date
HUP0200244A2 true HUP0200244A2 (en) 2002-07-29
HUP0200244A3 HUP0200244A3 (en) 2003-05-28

Family

ID=9543854

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200244A HUP0200244A3 (en) 1999-03-31 2000-03-30 Use of sex hormones for producing nasal pharmaceutical compositions useful in the treatment of undesirable uterine bleeding

Country Status (16)

Country Link
EP (1) EP1143978A2 (en)
JP (1) JP2002541076A (en)
KR (1) KR20010102464A (en)
CN (1) CN1346273A (en)
AU (1) AU3662300A (en)
BR (1) BR0008577A (en)
CA (1) CA2361885A1 (en)
EA (1) EA200100801A1 (en)
FR (1) FR2791572A1 (en)
HK (1) HK1044486A1 (en)
HU (1) HUP0200244A3 (en)
NO (1) NO20014022L (en)
NZ (1) NZ513672A (en)
PL (1) PL356767A1 (en)
WO (1) WO2000059447A2 (en)
ZA (1) ZA200106689B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383993A (en) * 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
NL8801670A (en) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan PHARMACEUTICAL PREPARATION.
US5922699A (en) * 1996-06-07 1999-07-13 Pherin Corporation 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
ES2273374T3 (en) * 1996-07-23 2007-05-01 Pherin Pharmaceuticals, Inc. STEROIDS AS UFO NEUROCHEMICAL STIMULATORS TO RELIEF PMS SYMPTOMS.

Also Published As

Publication number Publication date
WO2000059447A2 (en) 2000-10-12
AU3662300A (en) 2000-10-23
HK1044486A1 (en) 2002-10-25
PL356767A1 (en) 2004-07-12
NO20014022D0 (en) 2001-08-17
EA200100801A1 (en) 2002-04-25
NO20014022L (en) 2001-08-17
JP2002541076A (en) 2002-12-03
EP1143978A2 (en) 2001-10-17
ZA200106689B (en) 2002-11-14
NZ513672A (en) 2001-09-28
KR20010102464A (en) 2001-11-15
WO2000059447A3 (en) 2001-04-26
FR2791572A1 (en) 2000-10-06
HUP0200244A3 (en) 2003-05-28
CA2361885A1 (en) 2000-10-12
BR0008577A (en) 2002-10-01
CN1346273A (en) 2002-04-24

Similar Documents

Publication Publication Date Title
HU0103558D0 (en) Pharmaceutical composition for the treatment of stroke and traumatic brain insury
HUP0401192A3 (en) Use of photosenzitizing agent for preparation ot, of pharmaceutical composition for treating wounds
HUP0103494A2 (en) Process for intermittent administration use of growth hormone secretagogues for the manufacture of pharmaceutical compositions for intermittent administration and kit comprising thereof
HUP0200264A3 (en) Use of estrogen agonists/antagonists for producing pharmaceutical compositions suitable for the treatment of cancers
HUP0203437A3 (en) Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
IL211288A (en) Pharmaceutical vaginal composition for reducing or relieving uterine dysrhythmia and use of an anti-dysrhythmic treating agent in the manufacture of medicaments for vaginal administration in reducing or relieving uterine dysrhythmia
HUP0201187A2 (en) Use of ecteinascidin743 for producing pharmaceutical compositions suitable for treating cancer
HUP0301460A3 (en) Use of antiprogestins for producing pharmaceutical compositions for prohylaxis and treatment of hormone-dependent diseases
HUP0202233A3 (en) Derivatives and analogues of galanthamin, their use, pharmaceutical compositions containing them and process for the preparation of them
HUP0402323A3 (en) Preparation compositions containing acid-unstable physiologically acitve compounds and process for producing the same
HUP0104963A3 (en) Compositions for the treatment of skin diseases
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
HUP0402023A3 (en) Use of anastrozole in the preparation of pharmaceutical compositions for the treatment of post-menopausal women having early breast cancer
HUP0500958A3 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them, therapeutic use thereof and pharmaceutical compositions containing them
HUP0303910A3 (en) Use of kapp-opiate agonists for preparation of pharmaceutical composition for the treatment of bladder dieseases
GB0312566D0 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin
IL137275A0 (en) Pharmaceutical composition for the treatment of anal fissures
HUP0200244A3 (en) Use of sex hormones for producing nasal pharmaceutical compositions useful in the treatment of undesirable uterine bleeding
HUP0102696A3 (en) Use of growth hormone secretagogues for the preparation of pharmaceutical compositions stimulating or increasing appetite
HUP0204258A3 (en) Use of vitamin d-derivatives for preparation of pharmaceutical compositions useful in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
HUP0200993A3 (en) Thio-oxindole derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them
EP1304117A4 (en) Remedies for bone diseases
HUP0201875A2 (en) Use of antiprogestagens for preparing pharmaceutical compositions for contraception in combined therapy
EP1423125A4 (en) Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma